-
1Academic Journal
المؤلفون: Rahaf R. Almutairi, Atheer G. Almutairi, Afnan F. Alhallafi, Norah A. Almudawi, Mohammed Abdulaziz AlSulaiman, Asem M. Shadid, Ruaa Alharithy
المصدر: Dermatology Reports (2024)
مصطلحات موضوعية: Isotretinoin, acne, musculoskeletal side effects, arthritis, myositis, Dermatology, RL1-803
وصف الملف: electronic resource
-
2Academic Journal
المصدر: J Orofac Orthop ; ISSN:1615-6714
-
3
المؤلفون: Kathryn P. Gray, Karen N. Price, Brandon Young, Rudolf Maibach, Beat Thürlimann, Birgitte Bruun Rasmussen, Maria Olivia Biasi, Henrik J. Ditzel, Aron Goldhirsch, Isabelle Treilleux, Patrizia Dell'Orto, Roswitha Kammler, Patrick Neven, James M. Rae, Brian Leyland-Jones, Vernon Harvey, Bradley C. Long, Giuseppe Viale, Mark Bouzyk, Maria Bibi Lyng, Alan S. Coates, Meredith M. Regan, Olivia Pagani, Mark Abramovitz
المصدر: Leyland-Jones, B, Gray, K P, Abramovitz, M, Bouzyk, M, Young, B, Long, B, Kammler, R, Dell'Orto, P, Biasi, M O, Thürlimann, B, Lyng, M B, Ditzel, H J, Harvey, V J, Neven, P, Treilleux, I, Rasmussen, B B, Maibach, R, Price, K N, Coates, A S, Goldhirsch, A, Pagani, O, Viale, G, Rae, J M & Regan, M M 2015, ' CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial ', Breast Cancer Research and Treatment, vol. 151, no. 2, pp. 373-384 . https://doi.org/10.1007/s10549-015-3378-3
مصطلحات موضوعية: Cancer Research, Kaplan-Meier Estimate, Gastroenterology, Aromatase, Neoplasm Metastasis, Randomized Controlled Trials as Topic, biology, Letrozole, Middle Aged, Prognosis, Combined Modality Therapy, Tumor Burden, Postmenopause, Treatment Outcome, Oncology, Receptors, Estrogen, Female, Receptors, Progesterone, medicine.drug, medicine.medical_specialty, Genotype, medicine.drug_class, Single-nucleotide polymorphism, Breast Neoplasms, Polymorphism, Single Nucleotide, Article, Bone side effects, Breast cancer, Internal medicine, medicine, Biomarkers, Tumor, Humans, CYP19A1, Adverse effect, Alleles, Aged, Neoplasm Staging, Gynecology, Aromatase inhibitor, business.industry, Proportional hazards model, medicine.disease, Musculoskeletal side effects, Tamoxifen, Clinical Trials, Phase III as Topic, biology.protein, Neoplasm Grading, business